Latest News

Oslo, Norway, December 6, 2019 - Photocure ASA (OSE: PHO) will be presenting at the DNB Nordic Healthcare Conference in Oslo on December 12.

Oslo, Norway, November 29, 2019 - Photocure ASA (OSE: PHO) will be presenting at the Nordic-American Life Science Conference in New York on December 5.

Use of flexible Blue Light Cystoscopy at the first follow-up after TURBT* reduced the risk of tumor recurrence by 33% compared to white light alone. Randomized controlled multi-center study with 699 bladder cancer patients presented at Danish Urological Society meeting.

Oslo, Norway, 7 November 2019: Photocure ASA (OSE:PHO), today reported a revenue growth of 42% in local currency for the U.S. market in the third quarter of 2019, contributing to Hexvix/Cysview revenues of NOK 51.1 million (Q3 2018: NOK 43.5) and an EBITDA of NOK 8.3 million (NOK -3.1 million). The company entered into a license agreement with Asieris for the global commercialization of Cevira® and reiterates the significant revenue growth and profit opportunities in the U.S. market.

CMS final rule expands complexity adjustment for Hospital Outpatient from two to three procedure codes and increases the reimbursement due to the complexity adjustment for these procedures by $92 compared to 2019.

Photocure will present its third quarter report on Thursday 7 November 2019 at Hotel Continental, Oslo, Norway. The presentation will begin at 08:30 (CET).

Oslo, Norway, October 28th, 2019: today Photocure ASA announced highlights from the BLADDR 2019 congress, October 25-26 in Paris, France. The BLADDR congress is solely focused on bladder cancer and attracts bladder cancer experts from all over the world.

Successful experience with Blue Light Flexible Cystoscopy and Bladder Tumor destruction with Diode Laser in Outpatient Clinic.

Oslo, Norway, 19 September 2019, Photocure ASA (OSE: PHO) management will be presenting at the Norne Securities Vekst & Verdi Aksjeseminar in Vilnius, Lithuania on September 20 at 14:25 EEST/13:25 CEST.

Oslo, Norway, 3 September 2019, - Photocure ASA (OSE: PHO) management will be presenting at the 21st Annual Healthcare Conference to investors and industry peers in New York (US) on September 9 at 10:50 EDT. The conference is sponsored by H.C. Wainwright & Co. The presentation will be posted on www.photocure.com when held on September 9, 2019. 

Oslo, Norway, 7 August 2019: Photocure ASA (OSE:PHO), today reported a revenue growth of 41% in local currency for the U.S. market in the second quarter of 2019, contributing to Hexvix/Cysview revenues of NOK 52.1 million (Q2 2018: NOK 42.4) and a recurring EBITDA of NOK -2.6 million (NOK 0.7 million). The company continues to receive strong endorsement for the use of Blue Light Cystoscopy (BLC) with Cysview and reiterates the significant revenue growth and profit opportunities in the U.S. market.

Photocure will present its second quarter and first half year report on Wednesday 7 August 2019 at Hotel Continental, Oslo, Norway. The presentation will begin at 08:30 (CET).

Oslo, Norway, August 1, 2019 - Photocure ASA (OSE: PHO) management is conducting investor meetings in New York (US) on August 1, 2019, in connection with the European Biotech Investor Day, organized by Solebury Trout and sponsored by Goodwin LLC, Deutsche Bank, H.C. Wainwright and Nasdaq.

A new publication reviews this shift in the treatment paradigm for bladder cancer patients, discussing clinical benefits and cost management of the procedure.

Oslo, Norway July 1, 2019: Photocure ASA (Photocure, PHO: OSE), today announced that it has entered into a License Agreement providing Asieris Meditech Co., Ltd (Asieris) with a world-wide license to develop and commercialize Cevira® for the treatment of HPV induced cervical precancerous lesions. Under the agreement, Photocure will receive signing fees, development- and approval milestones, in addition to sales royalties.

Oslo, Norway, 19 June 2019: Photocure ASA (OSE: PHO), held an extraordinary general meeting on 19 June 2019 at 16:00 hours (CET).

Oslo, Norway, 18 June 2019 Photocure ASA (OSE: PHO), announces today that it has repurchased 1,694 own shares at NOK 0 per share in relation to the long-term incentive programme described in the stock exchange release on 7 May 2018.